



08/06/04

JPW

1647

\$

PTO/SB/21 (04-04)

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)

- | | | |
|--|--|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form (1 pp., submitted in duplicate)
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Supplemental Information
Disclosure Statement(5 pp.)
PTO/SB08A (2 pp.) PTO/SB08B (6 pp.)
*cite nos. 407-414, 431-448 and 500-542
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund

<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Technology Center (TC)
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Return Postcard |
|--|--|--|
- Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.
- *Not included in the "Total Number of Pages In This Submission"

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Townsend and Townsend and Crew LLP
Signature	Rosemarie L. Celli
Date	August 5, 2004


Reg. No. 42,397

CERTIFICATE OF TRANSMISSION/MAILING

Express Mail Label: EV 530 884 564 US

I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date August 5, 2004 and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Ron Anton
Signature	Ron Anton
Date	August 5, 2004

**FEE TRANSMITTAL
for FY 2004**

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$) 180**Complete if Known**

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Examiner Name	Christopher J. Nichols
Art Unit	1647
Attorney Docket No.	15270J-004751US

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit
Account
Number

20-1430

Deposit
Account
Name

Townsend and Townsend and Crew LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1)

(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims		Extra Claims		Fee from below		Fee Paid
Independent Claims						
Multiple Dependent						

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____


*Reduced by Basic Filing Fee Paid **SUBTOTAL (3)**

(\$180)

SUBMITTED BY**Complete (if applicable)**

Name (Print/Type)	Rosemarie L. Celli	Registration No. (Attorney/Agent)	42,397	Telephone	650-326-2400
Signature		Date	August 5, 2004		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



"Express Mail" Label No. EV 530 884 564 US

Date of Deposit August 5, 2004

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: Ron Anton

PATENT
Attorney Docket No.: 15270J-004751US
Client Reference No.: 209-US-CIP8AC1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No: 09/724,940
Applicant: Dale B. Schenk
Filed: November 28, 2000
TC/A.U. 1647
Examiner: Christopher J. Nichols

Docket No: 15270J-004751US
Customer No: 20350

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 AND §1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of reference numbers 407-414, 431-448 and 500-542 are enclosed. It is respectfully requested that the cited references be expressly

06/09/2004 WHEKONEN 00000002 201430 09724940

01 FC:1806 180.00 DA

considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98 issue fee paid on 10/07/03;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00 issue fee paid on 10/07/03;
09/723,927 filed 11/28/00 issue fee paid on 10/07/03;
09/723,762 filed 11/28/00 issue fee paid on 10/07/03;
09/724,102 filed 11/28/00 issue fee paid on 10/07/03;
09/724,489 filed 11/28/00 issue fee paid on 10/07/03;
10/816,022 filed 03/31/04;
10/816,529 filed 03/31/04;
10/815,391 filed 03/31/04;
10/815,353 filed 03/31/04;
15270J-004736US filed 03/31/04;
10/815,404 filed 03/31/04;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
09/580,015 filed 05/26/00;
09/724,940 filed 11/28/00;
09/724,961 filed 11/28/00 issue fee paid on 02/26/04;
09/580,018 filed 05/26/00 issue fee paid on 02/26/04;

09/724,552 filed 11/28/00 issue fee paid on 02/26/04;
09/723,544 filed 11/28/00;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00; issue fee paid on 02/26/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
15270J-004767US filed 04/12/04;
09/580,019 filed 05/26/00;
09/723,765 filed 11/28/00;
09/724,291 filed 11/28/00;
09/724,929 filed 11/28/00;
09/585,817 filed 06/01/00;
09/724,567 filed 11/28/00 notice of allowance mailed 03/02/04;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00 notice of allowance mailed 03/11/04;
09/724,570 filed 11/28/00;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/579,690 filed 05/26/00;
09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);
09/979,952 filed 04/04/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);

and,

09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;
10/789,273 filed 2/27/04;
10/232,030 filed 08/30/02;
10/388,389 filed 03/12/03

10/703,713 filed November 7, 2003
10/704,070 filed November 7, 2003
10/388,214 filed 03/12/03;
60/474,654 filed 05/30/03;
60/530,481 filed 12/17/03; and,
10/771,174 filed 02/04/04.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
60/137,010 filed 06/01/99;
60/251,892 filed 12/6/00;
60/137,047 filed 06/01/99; and,
60/136,655 filed 05/28/99.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;
60/444,150 filed 02/01/03; and,
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:


60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,

09/724,929 filed 11/28/00.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.


Applicant believes a fee of \$180 is required for submission of this statement, since it is being submitted after the first Office Action on the merits but before a final action. The Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	442	6,713,450 B2	03-30-2004	Frangione et al.	
	444	2004/0043418 A1	03-04-2004	Holtzman et al.	
	431	2003/0165496 A1	09-04-2003	Basi et al.	
	432	6,562,341 B2	05-13-2003	Prusiner et al.	
	440	2003/0068316 A1	04-10-2003	Klein et al.	
	453	2002/0058267 A1	05-16-2002	Ozenberger et al.	
	511	US-6,331,440	12-18-2001	Nordstedt, et al.	
	516	US-6,261,569	07-17-2001	Comis et al.	
	452	6,218,506 B1	04-17-2001	Krafft et al.	
	510	US-6,022,859	02-08-2000	Kiessling, et al.	
	512	US-5,891,991	04-06-1999	Wasco et al.	
	445	5,854,215	12-29-1998	Findeis et al.	
	446	5,817,626	10-06-1998	Findeis et al.	
	451	5,766,846	06-16-1998	Schlossmacher et al.	
	515	US-5,652,334	07-29-1997	Roberts	
	513	US-5,514,548	05-07-1996	Krebber et al.	
	514	US-5,470,951	11-28-1995	Roberts	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	433	WO	03/020212	A2	03-13-2003			
	441	WO	03/104437	A2	12-18-2003			
	443	WO	03/074081	A1	09-12-2003			
	447	WO	03/051374	A2	06-26-2003			
	450	WO	01/18169	A3	03-15-2001			
	454	WO	98/33815	A1	08-06-1998			
	455	WO	01/10900	A2	02-15-2001			
	456	WO	02/021141	A2	03-14-2002			
	457	WO	02/046237	A1	06-13-2002			
	458	WO	02/060481	A1	08-08-2002			


Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60277165 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

517	WO	94/05311	A1	03-17-1994			
518	WO	95/23166	A1	08-31-1995			
519	WO	00/26238	A2	05-11-2000			
520	WO	98/22120	A1	05-28-1998			
521	WO	98/05350	A1	02-12-1998			
522	WO	00/20027	A2	04-13-2000			
523	EP	752 886	B1	01-28-1998			
524	WO	95/05393	A2	02-23-1995			
525	WO	98/02462	A1	01-22-1998			
526	WO	99/06587	A2	02-11-1999			
527	WO	97/32017	A1	09-04-1997			
528	WO	97/08320	A1	03-06-1997			
529	WO	00/68263	A2	11-16-2000			
530	WO	98/08868	A1	03-05-1998			
531	WO	95/08999	A1	04-06-1995			
532	WO	96/37621	A2	11-28-1996			
533	AU	707083		07-01-1999			


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

Patents, Washington, DC 20231
60277165 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	448	ANDREW et al., <i>Current Protocols in Immunology</i> , 2.7.1-2.9.8 (1997).	
	484	ARENDIASH GW et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term A β vaccination: Task specificity and correlations between A β deposition and spatial memory," <i>DNA and Cell Biology</i> , 20(11):737-744 (2001)	
	485	BACSKAI BJ et al., "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy," <i>Nature Medicine</i> , 7(3):369-372 (2001)	
	504	BALBACH J et al., "Amyloid fibril formation by A β ₁₆₋₂₂ , a seven-residue fragment of the Alzheimer's β -amyloid peptide, and structural characterization by solid state NMR" <i>Biochemistry</i> , vol. 39, pp. 13748-59 (2000)	
	540	BENKIRANE, et al, "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <i>The Journal of Biological Chemistry</i> , 268(23):26279-26285 (1993).	
	461	BURDICK D et al., "Assembly and aggregation properties of synthetic Alzheimer's A4/ β amyloid peptide antigens," <i>J Biol Chme</i> , 267:546-55 (1992)	
	542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <i>J. Biol.Chem.</i> , 276(24):21562-70 (2001).	
	509	CIRRITO et al., "Amyloid β and Alzheimer disease therapeutics: the devil may be in the details," <i>J. Clin. Invest.</i> , 112:321-323 (2003)	
	462	CO et al."Chimeric and humanized antibodies with specificity for the CD33 antigen," <i>J Immunol</i> , 148:1149-1154 (1992)	
	541	CRIBBS et al, "All-D-Erantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All -L-Beta-Amyloids," <i>J. Biol. Chem.</i> , 272:7431-7436 (1997).	
	412	DAS et al., "Amyloid- β Immunization Effectively Reduces Amyloid Deposition in FcR γ Knock-Out-Mice," <i>J. Neuroscience</i> , 23(24):8532-8538 (2003).	
	469	DEMATTOS RB et al., "Peripheral anti-A β antibody alters CNS and plasma clearance and decreases A β burden in a mouse model of Alzheimer's disease3," <i>Proc Natl Acad Sci USA</i> 98(15):8850-8855	
	493	DEMATTOS RB et al., "Plaque-associated disruption of CSF and plasma amyloid- β (A β) equilibrium in a mouse model of Alzheimer's disease," <i>J Neurochem</i> , 81:229-236, (2002)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60277165 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4

of

8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

486	DICKEY CA et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β -amyloid 1-42 peptide," <u>DNA and Cell Biology</u> , 20(11):723-729 (2001)
436	DICKSON et al., "Neuroimmunology of Alzheimer's disease: a conference report," <u>Neurobiology of Aging</u> , 13(6):793-798 (1992), abstract only
407	ECK et al., <i>Goodman and Gilman's The pharmacological basis of therapeutics</i> , Chapter 5, pages 77-101 (1996)
475	EL-AGNAF OM et al., "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide," <u>Eur J Biochem</u> , 256(3):560-569 (1998)
501	ESLER W et al., "Point substitution in the central hydrophobic cluster of a human β -amyloid congener disrupts peptide folding and abolishes plaque competence" <u>Biochemistry</u> , vol. 35, pp. 13914-21 (1996)
539	FINDEIS, et al, "Modified peptide inhibitors of amyloid B-peptide polymerization," <u>Biochemistry</u> , 38:6791-6800 (1999).
464	FLOOD JF et al., "An amyloid β -Protein fragment, A β [12-28J, equipotently impairs post-training memory processing when injected into different limbic system structures," <u>Brain Res</u> , 663(2):271-276 (1994)
538	FLOOD, et al, "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic effect of amyloid B protein," <u>PNAS</u> , 91:380-384 (1994).
463	GHISO J et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <u>Biochem J</u> , 282 (Pt 2):517-522 (1992)
470	GIULIAN D et al., "Specific domains of β -amyloid from Alzheimer plaque elicit neuron killing in human microglia," <u>J Neurosci</u> , 16 (19):6021-6037 (1996)
503	GOREVIC P et al., "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern" <u>Biochem. and Biophys. Res. Commun.</u> , vol. 147, no. 2 (1987)
487	HAASS C et al., "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?" <u>Nature Neuroscience</u> , 4(9):859-860 (2001)
476	HE X-Y et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin," <u>J Immunol</u> , 160:1029-1035 (1998)
473	HILBICH C et al., "Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease" <u>J. Mol. Biol.</u> , 218:149-163 (1991)

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60277165 v1





PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

471	HILBICH C et al., "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease β A4 peptides" <u>J. Mol. Biol.</u> , 228:460-473 (1992)	
534	HOCK et al., "Antibodies against β -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <u>Neuron</u> , 38:542-554 (2003).	
413	HOLTZMAN et al., "A β immunization and anti-A β antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <u>Advanced Drug Delivery Reviews</u> , 54:1603-1613 (2002).	
434	KELLY, J. W., "Alternative conformations of amyloidogenic proteins govern their behavior," <u>Current Opinion in Structural Biology</u> , 6:11-17 (1996).	
488	KLEIN WL et al., "Targeting small A β oligomers: the solution to an Alzheimer's disease conundrum?" <u>Trends in Neurosciences</u> , 24(4):219-224 (2001)	
494	KOTILINEK LA et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <u>J Neurosci</u> , 22(15):6331-6335 (2002)	
465	KOUDINOV A et al., "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <u>Biochem & Biophys Res Comm</u> , 205:1164-1171 (1994)	
478	KUO YM et al., "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease," <u>Biochem Biophys Res Commun</u> , 257(3):787- 791 (1999)	
477	LAMBERT MP et al., "Diffusible, nonfibrillar ligands derived from A β 1-42 are potent central nervous system neurotoxins," <u>Proc Natl Acad Sci</u> , 95:6448-6453 (1998)	
489	LAMBERT MP et al., "Vaccination with soluble A β oligomers generates toxicity-neutralizing antibodies," <u>J Neurochem</u> , 79:595-605 (2001)	
490	LEE VM-Y et al., "A β immunization: Moving A β peptide from brain to blood," <u>PNAS</u> , 98(16):8931-8932 (2001)	
459	LEVITT M. "Molecular dynamics of native protein," <u>J. Mol Biol</u> , 168:595-620 (1983)	
481	LEVY A et al., "Immunization for Alzheimer's disease: A shot in the arm or a whiff?" <u>American Neurological Assoc</u> , 48:553-554 (2000)	
499	LUE L et al., "Soluble β -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease", <u>Am. J. Pathol.</u> , 1999, 155: pp 853-62	
502	MAGGIO J & MANTYH P "Brain Amyloid - A Physicochemical Perspective" <u>Brain Pathology</u> , vol. 6, 147-162 (1996)	

Examiner
SignatureDate
Considered


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60277165 v1





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6

of

8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

408	MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995).	
479	MCLEAN C et al., "Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease," <u>Amer Neurological Assoc</u> , 46:860- 866 (1999)	
439	NALBANTOGLU, J., "Beta-amyloid protein in Alzheimer's disease," <u>Can. J. Neurol. Sci.</u> , 18(3 suppl.):424-427 (1991), abstract only	
482	NASLUND J et al., "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline," <u>J Am Med Assoc</u> , 283:1571 (2000)	
409	ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995	
437	PERSSON et al., "IgG subclass-associated affinity differences of specific antibodies in humans," <u>J. Immunology</u> , 140(11):3875-3879 (1988), abstract only	
491	PODUSLO JF et al., "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," <u>Neurobiol Dis</u> , 8(4):555-67 (2001)	
460	QUEEN C et al., "A humanized antibody that binds to the interleukin 2 receptor," <u>Proc Natl Acad Sci USA</u> , 86:10029-10033 (1989)	
497	RAGUSI C et al., "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies" <u>J. Neurochem.</u> , Vol. 70, No. 5, pp 2099-105 (1998)	
414	SCHENK, D., "Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning," <u>Nature Reviews</u> , 3:824-828 (2002).	
466	SCHWARZMAN AL et al., "Transthyretin sequesters amyloid β protein and prevents amyloid formation," <u>Proc Natl Acad Sci</u> , 91:8368-8372, (1994)	
536	SELA et al, "Different roles of D-amino acids in immune phenomena," <u>FASEB J</u> , 11(6):449-456 (1999).	
505	SIMMONS L "Secondary structure of amyloid β peptide correlates with neurotoxic activity <i>in vitro</i> " <u>Molecular Pharmacology</u> , vol. 45, pp 373-9 (1994)	
438	SINGH, V. K., "Studies of neuroimmune markers in Alzheimer's disease," <u>Mol. Neurobiology</u> , 9(1-3):73-81 (1994), abstract only	


Examiner
Signature

Date
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60277165 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7

of 8

Complete if Known

Application Number	09/724,940
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004751US

411	SOLOMON et al., "The Amino Terminus of the β -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility," from <i>Progress in Alzheimer's and Parkinson's Diseases</i> , edited by Fisher et al., Plenum Press, New York, pages 205-211 (1995).
508	SOTO C et al., "The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation" <i>J. Biol. Chem.</i> , vol. 270, no. 7, pp 3063-67 (1995)
435	STERN et al., "Antibodies to the β -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood," <i>FEBS Letters</i> , 264(1):43-47 (1990).
496	STRBAK V et al., "Passive Immunization and Hypothalamic Peptide Secretion", <i>Neuroendocrinology</i> , 1993; 58:210-217
498	SUO et al., "Soluble Alzheimer's β -amyloid constricts the cerebral vasculature in vivo" <i>Neuroscience Letters</i> 257, pp 77-80 (1998)
467	TABATON M et al., "Soluble amyloid β -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <i>Biochem and Biophys Res Comm</i> , 200(3):1598-1603 (1994)
472	TELLER J et al., "Presence of soluble amyloid β -peptide precedes amyloid plaque formation in Down's syndrome" <i>Nature Medicine</i> , 2(1):93-95 (1996)
500	TJEMBERG L et al., "A molecular model for Alzheimer amyloid β -peptide fibril formation" <i>J. Biol. Chem.</i> , vol. 274, no. 18, pp 12619-25 (1999)
537	TJERNBERG, et al., "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," <i>J. Biol Chem.</i> , 272(19):12601-12605 (1997).
492	TOWN T et al., "Characterization of murine immunoglobulin G antibodies against human amyloid- β_{1-42} " <i>Neurosci Lett</i> , 307:101-104 (2001)
535	VAN REGENMORTEL et al., "D-peptides as immunogens and diagnostic reagents," <i>Curr. Opin. Biotech.</i> 9(4):377-382 (1998).
410	VERMA et al., "Gene therapy - promises, problems and prospects," <i>Nature</i> , 389:239-242 (1997).
495	WANG H-W et al., "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus," <i>Brain Research</i> , 924:133-140 (2002)
480	WANG J et al., "The levels of soluble versus insoluble brain A β distinguish Alzheimer's disease from normal and pathologic aging," <i>Experimental Neurology</i> , 158:328-337 (1999)

Examiner
Signature

Date
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60277165 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/724,940		
		Filing Date	November 28, 2000		
		First Named Inventor	Dale B. Schenk		
		Art Unit	1647		
		Examiner Name	Christopher J. Nichols		
Sheet	8	of	8	Attorney Docket Number	15270J-004751US

474	WINTER G et al., "Humanized antibodies" <u>Immunology Today</u> , 14(6):243-246 (1996)	
468	WISNIEWSKI T et al., "Alzheimer's disease and soluble A beta," <u>Neurobiol Aging</u> , 15(2):143-52 Review (1994)	
506	WOOD, A et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β /A4" <u>Biochemistry</u> , vol. 34 pp: 724-30 (1995)	
507	XU S and GASKIN F "Increased incidence of anti- β -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease" <u>Mechanisms of Ageing and Development</u> , vol. 94, pp 213-22 (1997)	
430	YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid β -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).	
483	ZLOKOVIC BV et al., "Clearance of amyloid β -peptide from brain: transport or metabolism?" <u>Nature Medicine</u> , 6(7):718-719 (2000)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60277165 v1